EDN1, endothelin 1, 1906

N. diseases: 679; N. variants: 23
Source: ALL
Disease Score gda Association Type Type Original DB Sentence supporting the association PMID PMID Year
CUI: C0020542
Disease: Pulmonary Hypertension
Pulmonary Hypertension
0.530 Biomarker phenotype RGD Rescue treatment with a Rho-kinase inhibitor normalizes right ventricular function and reverses remodeling in juvenile rats with chronic pulmonary hypertension. 20889845 2010
CUI: C0020542
Disease: Pulmonary Hypertension
Pulmonary Hypertension
0.530 Biomarker phenotype CTD_human Gene expression of endothelin-1 and endothelin receptor a on monocrotaline-induced pulmonary hypertension in rats after bosentan treatment. 20967148 2010
CUI: C0020542
Disease: Pulmonary Hypertension
Pulmonary Hypertension
0.530 Biomarker phenotype CTD_human The correlation of changes in PVR and plasma ET-1 levels in responders suggests that high plasma ET-1 is a key mediator of poor response in PH secondary to MS, after iNO therapy. 20929026 2010
CUI: C0020542
Disease: Pulmonary Hypertension
Pulmonary Hypertension
0.530 AlteredExpression phenotype LHGDN [Assessment of plasma endothelin level measurement in systemic sclerosis]. 17291632 2007
CUI: C0020542
Disease: Pulmonary Hypertension
Pulmonary Hypertension
0.530 AlteredExpression phenotype LHGDN Hemodynamic and clinical correlates of endothelin-1 in chronic thromboembolic pulmonary hypertension. 16864942 2006
CUI: C0020542
Disease: Pulmonary Hypertension
Pulmonary Hypertension
0.530 Biomarker phenotype LHGDN Induction of apoptosis and endothelin-1 secretion in primary human lung endothelial cells by HIV-1 gp120 proteins. 15979050 2005
CUI: C0020542
Disease: Pulmonary Hypertension
Pulmonary Hypertension
0.530 Biomarker phenotype CTD_human Finally, we suggest that these observations may help to explain why patients with pulmonary hypertension experience exacerbations after taking indomethacin and that the newly introduced selective cyclooxygenase-2 inhibitors may increase endothelin-1 production in susceptible patients, leading to vascular remodeling and the development of pulmonary hypertension. 12391278 2002
CUI: C0020542
Disease: Pulmonary Hypertension
Pulmonary Hypertension
0.530 Biomarker phenotype CTD_human These results indicate that chronic fenfluramine exposure potentiates the pulmonary vasoconstrictor response to ET-1, and suggests that elevated levels of serotonin may <prime> the pulmonary circulation to become hyperreactive to other vasoactive substances possibly leading to the development of disease states such as primary pulmonary hypertension. 9918753 1999
CUI: C0020542
Disease: Pulmonary Hypertension
Pulmonary Hypertension
0.530 Biomarker phenotype CTD_human To explain the increase in potency it is speculated that during the development of pulmonary hypertension the mechanism whereby ET-1 and NA contract pulmonary arteries may change from one in which Ca2+ influx plays only a minor role to one in which Ca2+ influx predominates, although no direct evidence to support this speculation has yet been obtained. 7549228 1994